AbbVie Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | AbbVie Inc |
Stock Symbol : | NYSE: ABBV |
Class Period Start: | 10/25/2013 |
Class Period End: | 09/18/2018 |
Lead Plaintiff motion: | 11/20/2018 |
Date Filed: | 09/21/2018 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Central District of California |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the November 20, 2018 lead plaintiff deadline in a class action lawsuit filed against AbbVie Inc (NYSE: ABBV) (“AbbVie” or “the Company”). The suit is pending in the U.S. District Court for the Central District of California and investors, who purchased AbbVie Inc securities between October 25, 2013 and September 18, 2018, have until November 20, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased AbbVie Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, was through illegal kickbacks and unlawful sales and marketing tactics; such practices would lead to heightened scrutiny by State governments and agencies; and as a result, defendants’ public statements were materially false and misleading at all relevant times. On September 18, 2018, California insurance regulators revealed that they were suing AbbVie, claiming that the Company provided illegal kickbacks to health care providers while promoting Humira. Following this news, NYSE: ABBV fell $2.76 per share, or almost 3%, to close at $92.61 per share on September 18, 2018. If you were negatively impacted by your investment in AbbVie Inc securities between October 25, 2013 and September 18, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |